Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth

被引：23
|
作者：
Wall, Michael D.
Oshin, Michael
Chung, Gavin A. C.
Parkhouse, Tony
Gore, Andrea
Herreros, Esperanza
Cox, Brian
Duncan, Ken
Evans, Brian
Everett, Martin
Mendoza, Alfonso
机构：
[1] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline, Harlow CM19 5AW, Essex, England
[3] GlaxoSmithKline, E-28760 Madrid, Spain
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 10期
关键词：
Mycobacterium tuberculosis; imidazopiperidines; InhA;
D O I：
10.1016/j.bmcl.2007.02.078
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The biological evaluation of imidazopiperidines as FAS II inhibitors of Mycobacterium tuberculosis growth has been carried out with a view to assessment of potential as lead compounds for the development of a new TB drug. A summary of the hit evaluation and current challenges is described herein. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2740 / 2744
页数：5
相关论文
共 50 条
  • [41] N-[5-(Diphenylphosphorylmethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethanesulfonamide
    Wu, Ya-Ming
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2013, 69 : O1673 - +
  • [42] 4-[(2-Bromobenzylidene)amino]-3(pyridin-4-yl)-1H-1,2,4-triazole-5(4H)-thione
    Gao, Wei
    Li, Xian
    Wang, Xin-Ling
    Yang, Jing
    Wu, Xue-Fen
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2012, 68 : O1996 - +
  • [43] Crystal structure of (E)-4-(6-(4-(2-(pyridin-4-yl)vinyl)phenoxy)pyrimidin-4-yl)morpholine, C21H20N4O2
    Bai, Su-Fen
    Liu, Jia-Xuan
    Li, Shan-Shan
    Tian, Chun-Yu
    La, Xiao-Jin
    ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES, 2022, 237 (04): : 583 - 585
  • [44] Diaquabis{5-(pyridin-2-yl-jN)-3-[4-(pyridin-4-yl)phenyl]-1H-1,2,4-triazol-1-ido-kappa N-1}cobalt(II)
    Li, Bin
    ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2013, 69 : M141 - +
  • [45] Synthesis and antimicrobial evaluation of 4-(1H-benzimidazol-2-yl)-N-[(1H-1,2,3-benzotriazol-1-yl) substituted phenylmethyl] amines
    Bhaskar, V. H.
    Kumar, T. Anil
    Kumar, M.
    Jayakar, B.
    INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY, 2007, 16 (03) : 297 - 298
  • [46] Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388):: A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor
    Gellibert, F
    de Gouville, AC
    Woolven, J
    Mathews, N
    Nguyen, VL
    Bertho-Ruault, C
    Patikis, A
    Grygielko, ET
    Laping, NJ
    Huet, S
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) : 2210 - 2221
  • [47] A NEW URICOSURIC SUBSTANCE, 5-[(1H-IMIDAZOL-1-YL)PHENYLMETHYL]-2-METHYL-1H-BENZIMIDAZOLE (C18H16N4)
    GRESSER, U
    ZOLLNER, N
    KLINISCHE WOCHENSCHRIFT, 1989, 67 (12): : 645 - 645
  • [48] (5-Hydroxy-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone monohydrate
    Kargar, Hadi
    Kia, Reza
    Froozandeh, Fatemeh
    Sadr, Moayad Hossaini
    Tahir, Muhammad Nawaz
    ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2011, 67 : O209 - U3199
  • [49] Metabolism study of morpholinium 2- ((4- (2-methoxyphenyl)-5-(pyridin-4-yl) -4H-1,2,4-triazole-3-yl)thio) acetate
    Varynskyi, Borys
    Kaplaushenko, Andriy
    CURRENT ISSUES IN PHARMACY AND MEDICAL SCIENCES, 2020, 33 (02) : 72 - 75
  • [50] SYNTHESIS OF 1-ANILINO-4H,5,6,7,8-TETRAHYDRO-1,2,3-TRIAZOLO[4,5-C]AZEPINONE-4
    GLUSHKOV, RG
    ZASOSOVA, IM
    OVCHAROVA, IM
    KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII, 1978, (10): : 1429 - 1429
12345